BioMed Research International
Volume 2019 (2019), Article ID 8515804, 1 page
https://doi.org/10.1155/2019/8515804

Corrigendum

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”

Eckard Hamelmann

Children’s Center Bethel, Ev. Klinikum Bielefeld gGmbH, Grenzweg 10, 33617 Bielefeld, Germany

Correspondence should be addressed to Eckard Hamelmann; eckard.hamelmann@evkb.de

Received 6 January 2019; Accepted 8 January 2019; Published 29 January 2019

Copyright © 2019 Eckard Hamelmann. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium” [1], there were errors in the description of Figure 1 and Table 1. The last sentence of Figure 1 should be updated from “LABA, long-acting β2-agonist” to “IL, interleukin; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; SABA, short-acting β2-agonist.” In addition, the last sentence of Table 1 should be updated from “LABA, long-acting β2-agonist; N/A, not applicable; NR, not reported; NS, not significant" to “ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; N/A, not applicable; NR, not reported.”

References

E. Hamelmann, “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium,” BioMed Research International, vol. 2018, Article ID 7473690, 9 pages, 2018.